UK-based GSK moved into the top five with nearly $38 billion
in drug sales for 2016.
GlaxoSmithKline (GSK) moved up a spot from number six last year to round out the 2016 top five pharma compa- nies. The UK-based drug maker’s revenue grew to $37.9
billion from $35 billion last year, driven by strong sales of HIV
drugs in the Pharmaceuticals segment.
The Pharmaceuticals segment is focused on providing medicines to treat a range of acute and chronic diseases. The broad
portfolio includes medicines for respiratory and HIV, in which
GSK are global leaders. Segment sales were approximately $20
billion. The respiratory business grew 2% driven by new products launched over the last four years, including Ellipta-based
products Breo, Anoro, Arnuity and Incruse as well as biologic
Nucala. HIV sales increased 37% driven primarily by strong performances from both Triumeq, a single-pill treatment combining
dolutegravir, abacavir and lamivudine, and Tivicay (dolutegravir),
an innovative integrase strand transfer inhibitor. The global HIV
business is managed through ViiV Healthcare, a company 78.3%
owned by GSK, with Pfizer and Shionogi the other shareholders.
ViiV Healthcare is growing rapidly, and accounts for over 20% of
GSK’s Vaccines business has a broad portfolio with vaccines
for people of all ages from babies and adolescents to adults and
older adults. The company delivers over two million vaccine doses
per day to people living in over 160 countries. Vaccines sales grew
26% roughly $4.6 billion during 2016. Performance was driven by
sales of new products including meningitis vaccines Bexsero and
Menveo, and there was also strong demand for Fluarix /FluLaval.
The Consumer Healthcare business, which develops and mar-
kets products in Wellness, Oral health, Nutrition and Skin health
categories, includes GSK’s seven global power brands—Otrivin,
Panadol, parodontax, Poligrip, Sensodyne, Theraflu and Voltaren.
Segment sales grew 19% to approximately $10 billion. At a brand
level, Sensodyne, Panadol and Otrivin performed strongly with
Sensodyne passing the $1 billion mark for the first time.
GSK reported balanced growth across its three global geog-raphies. U.S. sales grew 9% while in Europe sales grew 12% and
international market sales grew 8% for the year.
During the year GSK reported progress on several research collaborations. It exercised its option for an exclusive license to a
target under the respiratory diseases research collaboration with
Five Prime Therapeutics, triggering a $1.5 million payment to
Five Prime. The collaboration, established in 2012, aims to identify new therapeutic approaches to treat refractory asthma and
chronic obstructive pulmonary disease (COPD), with a focus on
identifying novel therapeutic targets. The collaboration was expanded in April 2014 to include two additional respiratory discovery programs and the research term was extended through
July 2016, which GSK committed to fund.
GSK has responsibility for further development and commercialization of products that incorporate or target the licensed
protein target. Five Prime is eligible to receive as much as $93
million in milestone payments for each product incorporating
the licensed protein. Five Prime is also eligible to receive royalties
on sales. The Five Prime discovery platform includes a library of
more than 5,700 extracellular proteins believed to encompass all
of the body’s medically important targets for protein therapeutics.
In another joint research effort, Adaptimmune Therapeutics
and GSK expanded the terms of their collaboration agreement to